Uma Borate, MBBS
The Ohio State University Comprehensive Cancer Center—James, United States
Patient Risk Stratification
Dr Borate describes MDS patient risk stratification as defined by IPSS-R and discusses using a patient’s risk category to determine appropriate treatment.
Uwe Platzbecker, MD, PhD
Hematology and Cell Therapy University Hospital in Leipzig, Germany
Novel Target TIM-3
Dr Platzbecker describes the role of TIM-3 as a novel target and how it relates to higher-risk MDS.
David Steensma, MD
Novartis Institutes for BioMedical Research (NIBR), United States
Dr Steensma discusses disease complexity in MDS, particularly immune dysfunction, and how it manifests differently depending on the severity of MDS.
Andrew Wei, MBBS, PhD
Alfred Hospital at Monash University, Australia
Dr Wei reviews unmet needs in higher-risk MDS, including poor prognosis and limited treatment options.